Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04762459 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04762459 · ClinicalTrials.gov record · last posted 2022-02-24

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Study acronym: APEX
StatusEnrolling by Invitation
PhasePhase 3
Started2021-08-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 24, 2022 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This is a multicenter, randomized, open label, phase III study.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2021-02-17; most recent amendment 2022-02-08. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-02-08
Status change Not Yet Recruiting→Enrolling by Invitationv2
Trial Details
NCT Number NCT04762459
Lead Sponsor Chinese Academy of Medical Sciences
Collaborators: Jiangsu Hansoh Pharmaceutical Co., Ltd., GeneCast Biotechnology Co., Ltd.
Conditions Non-small Cell Lung Carcinoma
Enrollment 606 participants
Start Date 2021-08-01
Primary Completion 2026-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2022-02-24